



EMBRACING NOVELTY IN HF_{rEF}

OPTIMIZING OUTCOMES IN PATIENTS WITH SYMPTOMATIC HIGH-RISK HF


Bibliography

- Armstrong PW, Pieske B, Anstrom KJ, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2020;382(20):1883–1893.
- Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. *JACC Heart Fail*. 2018;6(2):96–104.
- Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. *JACC Heart Fail*. 2019;7(1):1–12.
- Bhatt AS, Abraham WT, Lindenfeld J, et al. Treatment of HF in an era of multiple therapies: statement from the hf collaboratory. *JACC Heart Fail*. 2021;9(1):1–12.
- Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. *Handb Exp Pharmacol*. 2009;(191):485–506.
- Breitenstein S, Roessig L, Sandner P, Lewis KS. Novel sGC stimulators and sGC activators for the treatment of heart failure. *Handb Exp Pharmacol*. 2017;243:225–247.
- Butler J, Anstrom KJ, Armstrong PW. Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. *Circulation*. 2020;142(8):717–719.
- Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. *J Am Coll Cardiol*. 2019;73(8):935–944.
- Chamberlain AM, St Sauver JL, Gerber Y, et al. Multimorbidity in heart failure: a community perspective. *Am J Med*. 2015;128(1):38–45.
- Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. *JAMA*. 2011;306(15):1669–1678.
- Curtis LH, Mi X, Qualls LG, et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. *Am Heart J*. 2013;165(6):979–986.e1.
- Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. *JACC Heart Fail*. 2018;6(6):489–498.
- Dharmarajan K, Dunlay SM. Multimorbidity in Older Adults with Heart Failure. *Clin Geriatr Med*. 2016;32(2):277–289.
- Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? *Circulation*. 2012;126(4):501–506.
- Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-terminal pro-b-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. *JACC Heart Fail*. 2020;8(11):931–939.
- Felker G, Mann M, Douglas L. *Heart Failure: A Companion to Braunwald's Heart Disease*. Philadelphia, Pennsylvania: Elsevier; 2020.
- Fonarow GC. How well are chronic heart failure patients being managed? *Rev Cardiovasc Med*. 2006;7 Suppl 1:S3–11. PMID: 16955055.



- Gheorghide M, Marti CN, Sabbah HN, et al; Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential therapeutic target for heart failure. *Heart Fail Rev.* 2013;18(2):123–134.
- Greene SJ, Fonarow GC, Butler J. Risk profiles in heart failure: baseline, residual, worsening, and advanced heart failure risk. *Circ Heart Fail.* 2020;13(6):e007132.
- Greene SJ, Triana TS, Ionescu-Ittu R, et al. In-hospital therapy for heart failure with reduced ejection fraction in the United States. *JACC Heart Fail.* 2020;8(11):943–953.
- Heidenreich PA, Albert NM, Allen LA, et al; AHA Advocacy Coordinating Committee, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail.* 2013;6(3):606–619.
- Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA.* 2010;303(17):1716–1722.
- Hicks KA, Tchong JE, Bozkurt B, et al; American College of Cardiology; American Heart Association. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) [published correction appears in: *Circulation.* 2015;132(8):e129]. *Circulation.* 2015;132(4):302–361.
- Khan SU, Khan MZ, Alkhouli M. Trends of clinical outcomes and health care resource use in heart failure in the United States [published correction appears in: *J Am Heart Assoc.* 2020;9(16):e014577]. *J Am Heart Assoc.* 2020;9(14):e016782.
- Mann DL, Bonow RO, Libby, P, Zipes DP. *Braunwald's Heart Disease.* Philadelphia, Pennsylvania: Elsevier; 2015.
- McMurray JJV, DeMets DL, Inzucchi SE, et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. *Eur J Heart Fail.* 2019;21(11):1402–1411.
- McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med.* 2014;371(11):993–1004.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019;381(21):1995–2008.
- Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020;383(15):1413–1424.
- Patel UD, Hernandez AF, Liang L, et al. Quality of care and outcomes among patients with heart failure and chronic kidney disease: a Get with the Guidelines–Heart Failure Program study. *Am Heart J.* 2008;156(4):674–681.
- Pieske B, Patel MJ, Westerhout CM, et al; VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. *Eur J Heart Fail.* 2019;21(12):1596–1604.
- Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J.* 2007;154(2):260–266.
- Shah KS, Xu H, Matsouka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. *J Am Coll Cardiol.* 2017;70(20):2476–2486.
- Sumarsono A, Vaduganathan M, Ajufo E, et al. Contemporary patterns of medicare and medicaid utilization and associated spending on sacubitril/valsartan and ivabradine in heart failure. *JAMA Cardiol.* 2020;5(3):336–339.
- Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. *Circ Heart Fail.* 2020;13(11):e006977.



- 
- Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet*. 2020;396(10244):121–128.
- Valero-Elizondo J, Khera R, Saxena A, et al. Financial hardship from medical bills among nonelderly U.S. adults with atherosclerotic cardiovascular disease. *J Am Coll Cardiol*. 2019;73(6):727–732.
- Virani SS, Alonso A, Aparicio HJ, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation*. 2021;143(8):e254–e743.
- Wachter RM, Goldman L. Zero to 50,000—the 20th anniversary of the hospitalist. *N Engl J Med*. 2016;375(11):1009–1011.
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013;128(16):1810–1852.

